Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Integra LifeSciences Holdings is a medical devices business based in the US. Integra LifeSciences shares (IART) are listed on the NASDAQ and all prices are listed in US Dollars. Integra LifeSciences employs 3,800 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $55.00 |
|---|---|
| 52-week range | $53.57 - $76.70 |
| 50-day moving average | $58.95 |
| 200-day moving average | $64.82 |
| Wall St. target price | $72.57 |
| PE ratio | 29.4118 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $1.87 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $55 from 2022-07-01
| 1 week (2022-06-24) | 0.94% |
|---|---|
| 1 month (2022-06-03) | -9.36% |
| 3 months (2022-04-01) | -17.32% |
| 6 months (2022-01-03) | -19.60% |
| 1 year (2021-07-02) | -21.32% |
|---|---|
| 2 years (2020-07-02) | 12.89% |
| 3 years (2019-07-03) | 55.08 |
| 5 years (2017-07-03) | 1.68% |
Valuing Integra LifeSciences stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Integra LifeSciences's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Integra LifeSciences's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 29x. In other words, Integra LifeSciences shares trade at around 29x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Integra LifeSciences's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3763. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Integra LifeSciences's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Integra LifeSciences's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $407.2 million.
The EBITDA is a measure of a Integra LifeSciences's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $1.6 billion |
|---|---|
| Operating margin TTM | 18.4% |
| Gross profit TTM | $977 million |
| Return on assets TTM | 4.84% |
| Return on equity TTM | 9.96% |
| Profit margin | 10.04% |
| Book value | $19.43 |
| Market capitalisation | $4.6 billion |
TTM: trailing 12 months
We're not expecting Integra LifeSciences to pay a dividend over the next 12 months.
Integra LifeSciences's shares were split on a 2:1 basis on 3 January 2017. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Integra LifeSciences shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Integra LifeSciences shares which in turn could have impacted Integra LifeSciences's share price.
Over the last 12 months, Integra LifeSciences's shares have ranged in value from as little as $53.57 up to $76.7. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Integra LifeSciences's is 1.0957. This would suggest that Integra LifeSciences's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, and general surgery. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as asset management software and support, and after-market services. It also sells approximately 40,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, the company provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, bone grafts, and nerve and tendon repair products. The company offers its products directly through various sales forces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, Asia Pacific, and internationally.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.